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Abstract
Background: Intravascular ultrasound (IVUS) can be a useful tool during drug-eluting stents (DES) implantation as it
allows accurate assessment of lesion severity and optimal treatment planning. However, numerous reports have
shown that IVUS guided percutaneous coronary intervention is not associated with improved clinical outcomes,
especially in non-complex patients and lesions.
Methods: We searched the literature in Medline, the Cochrane Library, and other internet sources to identify
studies that compare clinical outcomes between IVUS-guided and angiography-guided DES implantation.
Random-effects model was used to assess treatment effect.
Results: Twenty eligible studies with a total of 29,068 patients were included in this meta-analysis. The use of IVUS
was associated with significant reductions in major adverse cardiovascular events (MACE, odds ratios [OR] 0.77,
95 % confidence intervals [CI] 0.71-0.83, P < 0.001), death (OR 0.62, 95 % CI 0.54-0.71, p < 0.001), and stent
thrombosis (OR 0.59, 95 % CI: 0.47-0.73, P < 0.001). The benefit was also seen in the repeated analysis of matched
and randomized studies. In stratified analysis, IVUS guidance appeared to be beneficial not only in patients with
complex lesions or acute coronary syndromes (ACS) but also patients with mixed lesions or presentations (MACE:
OR 0.69, 95 % CI: 0.60-0.79, p < 0.001, OR 0.81, 95 % CI 0.74-0.90, p < 0.001, respectively). By employing meta-regression
analysis, the benefit of IVUS is significantly pronounced in patients with complex lesions or ACS with respect to death
(p = 0.048).
Conclusions: IVUS guidance was associated with improved clinical outcomes, especially in patients with complex
lesions admitted with ACS. Large, randomized clinical trials are warranted to identify populations and lesion
characteristics where IVUS guidance would be associated with better outcomes.
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Background
Although there is evidence about the efficacy of drug-
eluting stents (DES) for treating coronary artery disease,
patients are not free of events as there is a considerable
risk of restenosis and stent thrombosis (ST) after DES
implantation [1]. Intravascular ultrasound (IVUS) with
its high resolution appears as a useful tool for evaluating
lesion severity, optimizing stent implantation and subse-
quently reducing adverse cardiovascular events [2, 3].
However, due to lack of universally identical IVUS guid-
ance criteria and large randomized clinical trials, the use
of IVUS for guiding DES implantation has been a con-
troversial issue among the interventionlists, with many
of them believing that its use increases cost and has only
a limited clinical benefit.
The results observed in a prespecified substudy of
ADAPT-DES (Assessment of Dual Antiplatelet Therapy
With Drug-Eluting Stents) showed that IVUS guidance
was strongly associated with lower incidences of ST,
myocardial infarction (MI) and major adverse cardiac
events (MACE) in all-comers population at 1 year
follow-up [4]. The improved outcomes noted in the
IVUS-guided group have been attributed to the longer
and lager stents used in the IVUS guidance group. How-
ever, a recent large observational study reported that
IVUS-guided percutaneous coronary intervention (PCI)
was not associated with improved long-term survival
compared with standard angiography-guided PCI [5].
The differences in outcomes noted in different studies
reflect the undefined role of IVUS during PCI in clinical
practice. Although meta-analyses have shown better out-
comes in patients undergoing IVUS guided PCI [6–8], to
date, there are limited data comparing IVUS guidance
with angiography guidance PCI in patients with complex
lesions or acute coronary syndromes (ACS).
Therefore, in this study we update our previous meta-
analysis and perform subgroup analysis with matched
and randomized studies and assess the effect on clinical
outcomes of IVUS guidance. We further investigate
whether IVUS guided DES implantation is associated
with a greater benefit in patients with complex lesions
or ACS.
Methods
Data sources and search strategy
We conducted the meta-analysis in accordance with the
PRISMA (Preferred Reporting Items for Systematic re-
views and Meta-Analyses) statement for studies that
evaluate healthcare interventions [9]. We searched the
literature in Medline, the Cochrane Library from January
1995 to October 2014, using combinations of the med-
ical subject headings “ultrasound, intravascular”, “IVUS”,
“IVUS-guided”, “angiography”, “angiography-guided”,
“drug-eluting stent” and “DES”. We used the Science
Citation Index as a cross reference to include studies that
met the search criteria. We also searched potential studies
from the conference proceedings of the American Col-
lege of Cardiology, the American Heart Association, the
European Society of Cardiology and the Transcatheter
Cardiovascular Therapeutics. Additionally, we reviewed
the reference of the selected articles and earlier meta-
analyses for related documents.
Study identification and data extraction
Two investigators (PS and CXY) independently con-
ducted the literature search, data extraction and quality
evaluation through a standard method. Differences were
resolved by consensus with third investigator (ZYJ).
Studies were included in the current meta-analysis if
they met the following predetermined criteria [4, 10–28]:
(1) clinical research published in peer-reviewed journals
with complete data; (2) comparison of IVUS- versus
angiography-guided DES implantation; and (3) at least
6 months follow up. Studies that included bare metal
stents (BMS) and DES implantation and did not provide
separately the DES data were excluded. Two investi-
gators (PS and CXY) extracted the baseline informa-
tion, which included the study name, study design, sample
size, follow-up duration, patients’ baseline characteristics
(mean age, sex distribution, and risk factors), lesion and
procedural characteristics, and clinical outcomes. The
Newcastle-Ottawa-Scale (NOS) scale was used for quality
assessment, including assessment of selection of the ex-
posed and unexposed cohort, comparability of the two co-
horts, and outcome assessment [29]. The qualities of
randomized trials were assessed by the Jadad score [30].
Clinical endpoints
The endpoints of the present analysis included: (1) all-
cause death (in 2 studies [11, 13] that only reported
cardiac death was included instead), (2) MACE, (3) ST
(definite or probable ST, according to the definition of
the Academic Research Consortium), (4) MI (in 1 study
[14] only the Q-wave MI was reported while others re-
ported both non-Q-wave MI and Q-wave MI), (5) target
vessel revascularization (TVR), and (6) target lesion revas-
cularization (TLR). Repeated-analyses were performed in
patients with complex lesions or ACS compared to mixed
lesions or any presentations and among propensity-
matched and randomized studies.
Statistical analysis
The guideline of the Cochrane Handbook for Systematic
Reviews of Interventions was implemented in this meta-
analysis [31]. Standard data extraction and calculation
were used to improve efficiency and reliability of the
analysis [32]. Random-effects model was adopted to
measure overall treatment effect expressed as odds ratios
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(OR) and 95 % confidence intervals (CI). Forest plots
were generated for graphical presentations of clinical
outcomes with IVUS- versus angiography-guided groups.
We assessed heterogeneity of the study using chi-square
tests (p > 0.1 showed no significant heterogeneity among
studies) and I2 statistic (I2 > 25 %, >50 %, >75 % showed
low, moderate and severe heterogeneity, respectively). All
p-values were two-tailed and the statistical significance
was considered at <0.05. In case there was heterogeneity
among the studies, we conducted sensitivity analyses to
clear the source of the heterogeneity. We tested the in-
teraction between patients with complex lesions or ACS
versus patients with mixed lesions or any clinical presen-
tations by means of weighted least squares random-effect
meta-regression, with weighting provided by the inverse
of the variance of each study, patients with complex le-
sions or ACS (coded as 1 versus patients with mixed
or any clinical presentations coded as 0) as random
factor, and the natural logarithm of the individual OR
as dependent variable [29]. The Egger’s linear regres-
sion test was performed for asymmetry of the publi-
cation or reporting bias [33]. All statistical analysis
was performed with STATA 12.0 (Stata Corp, College
Station, TX, USA).
Ethics
This meta-analysis didn’t require ethical approval.
Results
Inclusion of studies
In total, twenty eligible studies were included in this
meta-analysis (Fig. 1). Out of 20 studies, 3 studies were
prospective, randomized trials [10–12], and 17 were ob-
servational registries [4, 13–28]. In addition, 9 of the in-
cluded studies had performed sub-analysis after
propensity score matching [14, 15, 17, 18, 20, 21, 26–
28]. Therefore, 13 studies enrolled only patients with
complex lesions or ACS, including 4 for left main dis-
ease [13, 15, 26, 28], 3 for bifurcation [16, 17, 21], 1 for
chronic total occlusion (CTO) [27], 1 for long lesion
[12], 1 for ST-segment elevation MI [24], and 3 for com-
bined complex lesions [10, 11, 24].
Out of 29,068 patients included in this study, 13,552
(46.6 %) patients underwent IVUS-guided DES implant-
ation and 15,516 (53.4 %) angiography-guided DES im-
plantation. The study characteristics are summarized in
Table 1. The mean weighted follow-up was 20.8 months.
Lesion and procedural characteristics are shown in
Table 2.
Effect of IVUS guidance on clinical outcomes
MACE were reported in 19 of the 20 included studies.
The summary result was in favor of IVUS-guided DES
implantation in risk of MACE (OR 0.77, 95 % CI 0.71-
0.83, P < 0.001; Fig. 2a). Statistical analysis did not show
Fig. 1 Flow diagram of meta-analysis
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Table 1 Study design and baseline characteristics
Study Year Design Sample size F/U Months Age years Male DM Hyperlipidemia LVEF, % Renal insufficiency Smoker Study quality
(Max = 9)
P Agostoni [13] 2005 Observational 24/34 14 62/64 15/25 9/10 15/23 52/44 NA/NA 4/7 7
P Roy [14] 2008 Observational 884/884 12 66/66 613/619 317/304 762/770 47/48 110/112 186/181 9
SJ Park [15] 2009 Observational 145/145 36 64/65 102/102 49/49 42/44 60/61 7/6 28/30 9
SH Kim [16] 2010 Observational 308/112 48 59/60 221/80 61/24 134/99 60/59 3/1 109/40 8
J Jakabcin [10] 2010 RCT 105/105 18 59/60 77/75 44/47 66/69 NA/NA NA/NA 42/37 4a
JS Kim [17] 2011 Observational 487/487 36 62/62 324/326 155/162 168/170 60/59 15/15 106/111 9
BE Claessen [18] 2011 Observational 631/873 24 64/65 469/652 190/316 533/740 NA/NA 54/97 70/94 9
SH Hur [19] 2011 Observational 2765/1816 36 59/62 1982/1240 622/463 1305/1108 59/57 83/105 979/636 7
KW Park [20] 2012 Observational 619/802 12 62/63 393/524 233/309 468/610 NA/NA NA/NA 147/233 8
SL Chen [21] 2012 Observational 324/304 12 63/65 261/227 60/54 108/304 61/60 NA/NA 147/154 8
ADAPT-DES [4] 2013 Observational 3349/5234 12 63/64 2457/3901 1048/1735 2287/4093 NA/NA 536/894 851/1088 9
Chieffo A [11] 2013 RCT 142/142 24 64/64 117/109 34/38 100/109 55/56 NA/NA 49/44 4a
RESET [12] 2013 RCT 269/274 12 63/64 177/150 85/82 165/165 55/54 NA/NA 58/47 5a
YJ Youn [22] 2011 Observational 125/216 36 60/61 93/136 34/71 28/24 45/48 3/6 94/125 8
YW Yoon [23] 2013 Observational 662/912 12 61/63 428/592 184/270 403/512 NA/NA NA/NA 167/236 8
SG Ahn [24] 2013 Observational 49/36 24 65/65 30/22 13/11 14/9 54/56 5/2 16/14 7
IRIS-DES [25] 2013 Observational 1616/1628 24 62/64 1115/1034 500/516 645/548 60/59 48/57 492/478 7
Hernandez [26] 2014 Observational 505/505 36 66/67 404/397 183/175 314/284 55/55 35/31 148/161 8
SJ Hong [27] 2014 Observational 206/328 24 62/63 159/234 62/124 89/116 NA/NA NA/NA 58/93 9
XF Gao [28] 2014 Observational 337/679 12 66/67 274/526 109/232 228/487 59/57 88/214 111/230 9
Data are presented as IVUS guidance/ angiography guidance. The Newcastle-Ottawa-Scale was used for quality assessment of observational studies
Abbreviation: DM diabetes mellitus; F/U follow-up; LVEF left ventricular ejection fraction; MI myocardial infarction; NA not available; RCT randomized controlled trials













significant heterogeneity (heterogeneity chi-square = 23.40,
I2 = 23.1 %, p = 0.176).
IVUS guidance was associated with a significantly low
risk of mortality, compared with angiography guidance
(OR 0.62, 95 % CI 0.54-0.71, p < 0.001; Fig. 2b). Evidence
of statistical heterogeneity was not observed among
the studies (heterogeneity chi-square = 22.77, I2 = 20.9 %,
p = 0.200).
The occurrence of definite/probable ST was reported
in 19 studies. IVUS guidance appeared to be associated
with a significantly low incidence of ST (OR 0.59, 95 %
CI: 0.47-0.73, P < 0.001; Fig. 2c). There is no statistical
heterogeneity in these studies (heterogeneity chi-square =
19.37, I2 = 12.2 %, p = 0.308).
MI was reported in 18 studies and the pooled result
showed that IVUS guidance was associated with a signifi-
cantly low risk of MI (OR 0.64, 95 % CI: 0.55-0.75, P <
0.001; Fig. 2d). The pooled OR for TLR associated with
IVUS guidance versus angiography guidance was 0.81 (95
% CI: 0.69-0.94, P = 0.005; Fig. 2e) while the pooled OR
for TVR was 0.86 (95 % CI: 0.77-0.97, P = 0.012; Fig. 2f).
Statistical heterogeneity was not found in MI (heterogen-
eity chi-square = 16.80, I2 = 4.8 %, p = 0.398), but there
was heterogeneity in TLR and TVR (heterogeneity chi-
square = 20.27, I2 = 45.7 %, p = 0.042; heterogeneity chi-
square = 24.33, I2 = 46.6 %, p = 0.028, respectively).
Outcomes in propensity-matched and randomized studies
In the repeated analysis of propensity-matched and ran-
domized studies, a total of 8,331 patients were included.
Repeated analysis confirmed that IVUS guidance was as-
sociated with a significant reductions in MACE (OR
0.79, 95 % CI: 0.70-0.88, P < 0.001, Fig. 3a), death (OR
0.64, 95 % CI: 0.52-0.79, P < 0.001, Fig. 3b), ST (OR 0.55,
95 % CI: 0.39-0.78, P = 0.001, Fig. 3c), MI (OR 0.69, 95 %
CI: 0.56-0.85, P < 0.001, Fig. 3d), and TVR (OR 0.82,
95 % CI: 0.68-0.98, P = 0.028, Fig. 3f ). No statistical dif-
ference was observed in TLR (OR 0.92, 95 % CI: 0.76-
1.11, P = 0.377, Fig. 3e).
Stratified analysis in patients with complex lesions or ACS
Sub-analysis was performed to compare IVUS-guided ver-
sus angiography-guided PCI with DES for patients with
complex lesions or ACS. Thirteen studies with 6,393 pa-
tients were eligible for this sub-analysis. IVUS guidance
was associated with a low risk of MACE (OR 0.69, 95 %
CI: 0.60-0.79, p < 0.001), death (OR 0.52, 95 % CI: 0.40-
0.67, p < 0.001), and ST (OR 0.41, 95 % CI: 0.25-0.69, p =
0.001) for patients with complex lesions or ACS, when
compared to patients with mixed lesions or any clinical
presentation (MACE [OR 0.81, 95 % CI: 0.74-0.90, p <
0.001], death [OR 0.67, 95 % CI: 0.56-0.80, p < 0.001], and
ST [OR 0.64, 95 % CI: 0.50-0.82, p < 0.001], respectively)
Table 2 Patient, lesion, and procedural characteristics
Study Lesion number LM LAD LCX RCA Ostial lesion Stent number Stent diameter Stent length
P Agostoni [13] NA/NA 24/34 0/0 0/0 0/0 7/3 1.5/1.4 3.2/3.2 27/23
P Roy [14] 1.7/1.7 26/30 427/433 320/305 446/450 50/48 1.5/1.5 3.05/3.09 20.7/20.1
SJ Park [15] NA/NA 145/145 0/0 0/0 75/80 61/62 1.23/1.24 NA/NA 35.2/35.6
SH Kim [16] 1.4/1.2 NA/NA NA/NA NA/NA NA/NA 61/9 NA/NA NA/NA 34/26
J Jakabcin [10] 1.2/1.2 3/4 59/57 12/16 30/25 NA/NA NA/NA NA/NA 23.6/22.1
JS Kim [17] NA/NA 17/19 404/402 63/63 20/22 NA/NA 1.3/1.2 NA/NA NA/NA
BE Claessen [18] 1.9/1.8 30/20 349/321 226/307 165/316 55/59 NA/NA 3.1/3.0 23.5/24.5
SH Hur [19] NA/NA 232/45 1628/904 340/390 686/612 312/84 1.7/1.6 3.3/3.1 38.6/36.7
KW Park [20] 1.4/1.3 0/0 455/502 171/250 227/315 NA/NA 1.3/1.2 3.19/3.06 30.7/23.0
SL Chen [21] NA/NA 137/83 129/186 44/26 14/9 NA/NA 1.26/1.20 3.25/3.16 32.7/30.5
ADAPT-DES [4] 1.48/1.52 146/171 NA/NA NA/NA NA/NA NA/NA 1.73/1.71 NA/NA 33.6/31.7
Chieffo A [11] NA/NA NA/NA NA/NA NA/NA NA/NA NA/NA NA/NA 2.95/2.86 23.9/23.2
RESET [12] NA/NA 0/0 167/185 41/35 61/54 NA/NA NA/NA NA/NA 32.4/32.3
YJ Youn [22] NA/NA 1/2 75/101 7/21 42/92 NA/NA 1.4/1.2 3.18/3.03 34.8/29.5
YW Yoon [23] NA/NA 0/0 441/566 131/255 163/344 NA/NA NA/NA NA/NA 20.4/20.1
SG Ahn [24] NA/NA 0/0 29/16 6/2 14/18 8/2 2.8/2.2 3/2.87 74/66
IRIS-DES [25] NA/NA 148/26 1019/958 NA/NA NA/NA NA/NA 1.44/1.16 3.28/3.1 35.5/26.9
Hernandez [26] 1.47/1.5 505/505 NA/NA NA/NA NA/NA 151/145 NA/NA NA/NA NA/NA
SJ Hong [27] NA/NA 6/4 91/123 34/75 NA/NA NA/NA 1.7/1.42 2.96/2.83 44.6/36.9
XF Gao [28] 1.2/1.3 337/679 224/479 125/324 146/369 32/59 1.5/1.4 3.5/3.4 35.4/33.3
Data are presented as IVUS guidance/ angiography guidance
Abbreviation: LM left main coronary artery; LAD left anterior descending artery; LCX left circumflex artery; RCA right coronary artery; NA not available
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Fig. 2 Clinical outcomes after DES implantation with IVUS versus angiography guidance. Abbreviation: MACE =major adverse cardiac events;
OR = odds ratios; CI = confidence intervals
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(Fig. 4). By employing meta-regression analysis, the benefit
of IVUS guidance is significantly pronounced in patients
with complex lesions or ACS with respect to death (p =
0.048).
Sensitivity analyses and publication bias
Sensitivity analyses of the lesion subsets did not change
the reported results. There was no evidence of publica-
tion bias through the Egger’s linear regression analysis
Fig. 3 Outcomes in propensity-matched and randomized studies. Abbreviation: MACE =major adverse cardiac events; OR = odds ratios;
CI = confidence intervals
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(p = 0.455 for MACE, p = 0.395 for death, P = 0.217 for
ST, p = 0.319 for MI, p = 0.738 for TLR, P = 0.103 for
TVR, Fig. 5). Assessment of publication bias using the
logarithm of relative risk showed a symmetric funnel
plot and confirmed no evidence of publication bias.
Discussion
This meta-analysis involving 29,068 patients has shown
that IVUS guidance for DES implantation was associated
with significantly improved clinical outcomes, when
compared with angiography guidance. Similar results
were observed in the repeated-analyses of matched and
randomized studies. IVUS guidance appeared to have a
more beneficial effect in patients with complex lesions
or ACS than patients with mixed lesions or presenta-
tions with respect to death.
The value of IVUS in guiding DES implantation is still
controversial. IVUS-guided PCI could result in larger
minimum luminal diameter (MLD) and reduce the inci-
dence of strut malapposition, but does not appear to im-
prove clinical outcomes compared to angiography
guidance [11], especially in patients with simple lesions.
The lack of robust evidence supporting the value of
IVUS imaging as well as the fact that IVUS increases
Fig. 4 Stratified analysis in patients with complex lesions or acute coronary syndromes. Abbreviation: MACE =major adverse cardiac events; OR =
odds ratios; CI = confidence intervals
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considerably procedure time and cost have restricted the
clinical applications of this modality. However, recent
meta-analyses comparing outcomes between patients
undergoing IVUS-guided PCI versus patients undergo-
ing angiography-guided PCI have showed significantly
low rate of MACE, in the IVUS-guided group [7]. The
results reported in the present analysis are agreement
with those reported in previous studies, showing that
IVUS may play a fundamental role in the treatment of
patients with coronary artery disease as it significantly
reduces clinical adverse events.
Potential differences in the baseline characteristics of
the patients recruited in each study are likely to intro-
duce bias and affect the reported results. To address this
limitation we performed repeated analysis in propensity-
matched and randomized populations. Of note, the re-
peated results confirmed that IVUS guidance increased
safety and efficacy during the PCI. In the randomized
AVIO trial [11], the occurrence of cumulative MACE in
the IVUS guided group was apparently lower than the
angiography guided group (16.9 % vs. 23.2 %) at 2 years
follow-up. Although the study failed to show statistical
Fig. 5 Publication bias. Abbreviation: MACE =major adverse cardiac events; TLR = target lesion revascularization; TVR = target vessel
revascularization; OR = odds ratios; CI = confidence intervals
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significant differences in this composite endpoint, this
should be predominantly attributed to the limited sam-
ple size (n = 284).
In the present meta-analysis we found an increased
beneficial effect of IVUS guidance in complex lesions
and in patients admitted with ACS with respect to death.
Similarly, in the substudy of ADAPT-DES (Assessment
of Dual Antiplatelet Therapy With Drug-Eluting Stents),
the benefits of IVUS in reducing MACE were more evi-
dent in patients with ACS and complex lesions [4]. In-
deed, IVUS is recommended for sizing bifurcation stents
and evaluating lesion severity in the consensus docu-
ments from European bifurcation club [34]. Apart from
this, IVUS also has an accurate correlation between
IVUS derived minimal area and fractional flow reserve
(FFR) to facilitate detection of hemodynamically signifi-
cant left main lesions [35]. A recent large registry that
recruited patients who had unprotected left main PCI
showed that IVUS guidance was associated with signifi-
cant reductions of 1-year cardiac death (1.7 % vs.5.2 %,
p = 0.023), TVR (3.4 % vs. 10.0 %, p = 0.002) and MACE
(16.2 % vs. 24.4 %, p = 0.014) [28]. Consistently, a recent
study from Europe also showed a low rate of MACE
(11.7 % vs. 16 %, p = 0.04) in patients with left main cor-
onary disease having IVUS guided PCI [26]. In the
present sub-group analysis for patients with complex le-
sions or ACS, we included studies with IVUS guided
PCI for left main stem disease, bifurcation, CTO, small
vessel, long lesion, and ACS. Although some studies
have also reported opposing results, there was a signifi-
cant favorable effect of IVUS guidance on clinical out-
comes in this subset of patient populations [24, 25, 28].
Recently, Fröhlich GM et al. reported the long-term
survival of a large cohort study (Angiography versus
IVUS or intracoronary pressure wire-derived measure-
ments of FFR to guide elective or urgent PCI) in patients
undergoing PCI at eight London centers between 2004
and 2011 (n = 41,688) [5]. Surprisingly, patients who
underwent IVUS had a higher adjusted mortality com-
pared with angiography guided PCI (hazard ratio: 1.39;
95 % CI: 1.09-1.78; P = 0.009), although this difference
was no longer statistically significant in a matched pair
of 803 patients. Obviously, the adjusted analysis is likely
to introduce an error; in addition the absence of import-
ant procedural and lesion characteristics which may have
a critical impact on clinical outcomes did not allow
drawing safe conclusions. Moreover, the absence of pre-
specified criteria for IVUS imaging is also likely to have
affected the reported results. These limitations could po-
tentially explain the discrepancy noted between this
study and our analysis which included a large sample
size, the sub-analysis of matched and randomized stud-
ies, and the stratified analysis on complex lesions or
ACS, which showed that IVUS guided PCI reduces
death, ST, and MACE at a mean weighted follow-up of
20.8 months.
The results of the present meta-analysis and the in-
consistent findings of previous studies underscore the
need to design a large randomized control trial that
would have enough power to investigate the efficacy of
IVUS guided PCI in the 2nd generation DES era. Cer-
tainly, a cost-effectiveness analysis of IVUS use during
PCI should be incorporated into the additional benefit
on clinical outcomes.
Limitations
Our study has several limitations. It is a meta-analysis
and shares the limitations from the original studies. The
inability to adjust the baseline characteristics between
the 2 studied groups may introduce remarkable bias.
However, the findings consistently showed that IVUS
guidance was associated with improved outcomes in the
all included studies and the repeated analysis that in-
cluded matched and randomized studies. The current
study was not able to differentiate the impact of IVUS
guidance in patients treated with either first or newer
generation DES.
Conclusions
IVUS guided PCI was associated with better clinical out-
comes than angiography guided DES implantation. The
benefit appeared more significant in the subgroup of pa-
tients with complex lesions or ACS with respect to
death. Large scale randomized control trials are needed
to identify which types of lesion morphology and sub-
groups of patients will be associated with better clinical
outcomes after the IVUS guided DES implantation.
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